Product characteristics of human cell line recombinant factor VIII (human-cl rhFVIII)

被引：0
|
作者：
Sandberg, H. [1 ]
Ramstrom, M. [1 ]
Stenlund, P. [1 ]
Kannicht, C. [2 ]
Agerkvist, I. [1 ]
机构：
[1] Octapharma AB, Stockholm, Sweden
[2] Octapharma, Mol Biochem, Berlin, Germany
来源：
HAEMOPHILIA | 2011年 / 17卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
11
引用
收藏
页码：356 / 357
页数：2
相关论文
共 50 条
  • [1] Product characteristics of human cell line recombinant factor VIII, (human-cl rhFVIII)
    Sandberg, H.
    Ramstrom, M.
    Stenlund, P.
    Kannicht, C.
    Agerkvist, I.
    [J]. HAEMOPHILIA, 2010, 16 : 39 - 39
  • [2] Characteristics of the first human cell line recombinant human factor VIII (human-cl rhFVIII)
    Sandberg, H.
    Agerkvist, I
    Kannicht, C.
    Ramstrom, M.
    Stenlund, P.
    Dadaian, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 513 - 514
  • [3] The First Human Cell Line Recombinant Factor VIII (Human-cl rhFVIII) - Functional Properties and Differences From Currently Available Recombinant Factor VIII Products.
    Schwartz, Bruce A.
    Sandberg, Helena
    Agerkvist, Irene
    Kannicht, Christoph
    Ramstrom, Margareta
    Stenlund, Peter
    Oswaldsson, Ulla
    Brunberg, Tobias
    [J]. BLOOD, 2009, 114 (22) : 532 - 532
  • [4] Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety
    Lissitchkov, T.
    Hampton, K.
    von Depka, M.
    Hay, C.
    Rangarajan, S.
    Tuddenham, E.
    Holstein, K.
    Huth-Kuehne, A.
    Pabinger, I.
    Knaub, S.
    Bichler, J.
    Oldenburg, J.
    [J]. HAEMOPHILIA, 2016, 22 (02) : 225 - 231
  • [5] Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line
    Winge, Stefan
    Yderland, Louise
    Kannicht, Christoph
    Hermans, Pim
    Adema, Simon
    Schmidt, Torben
    Gilljam, Gustav
    Linhult, Martin
    Tiemeyer, Maya
    Belyanskaya, Larisa
    Walter, Olaf
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2015, 115 : 165 - 175
  • [6] Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII
    Sandberg, Helena
    Kannicht, Christoph
    Stenlund, Peter
    Dadaian, Marina
    Oswaldsson, Ulla
    Cordula, Carina
    Walter, Olaf
    [J]. THROMBOSIS RESEARCH, 2012, 130 (05) : 808 - 817
  • [7] Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics
    Klukowska, A.
    Szczepanski, T.
    Vdovin, V.
    Knaub, S.
    Jansen, M.
    Liesner, R.
    [J]. HAEMOPHILIA, 2016, 22 (02) : 232 - 239
  • [8] Personalizedprophylaxis with Human-CL RHFVIII in hemophilia A patients
    Klamroth, R.
    Lissitchkov, T.
    Rusen, L.
    Walter, O.
    Knaub, S.
    Bichler, J.
    Pasi, J.
    Tiede, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 850 - 851
  • [9] A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells
    Knaub, Sigurd
    Tiede, Andreas
    Lissitchkov, Toshko
    Valentino, Leonard A.
    Powell, Jerry Sherman
    Manco-Johnson, Marilyn J.
    [J]. BLOOD, 2011, 118 (21) : 1423 - 1423
  • [10] Individualized Prophylaxis with Human-cl rhFVIII* in Adult PTPs with Severe Hemophilia A
    Kessler, C.
    Boggio, L.
    Bichler, J.
    Pezeshki, G.
    Wang, M.
    Ducore, J.
    [J]. HAEMOPHILIA, 2017, 23 : 20 - 21
12345